Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.

W, Jonat; M, Kaufmann; W, Sauerbrei; R, Blamey; J, Cuzick; M, Namer; I, Fogelman; Haes JC, de; Matteis A, de; A, Stewart; W, Eiermann; I, Szakolczai; M, Palmer; M, Schumacher; M, Geberth; B, Lisboa

doi:10.1200/jco.2002.05.042

Public

Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.

Shared by NobleBlocks on Dec 1, 2002 • 12:00 AM UTC

Authors:

Jonat W

Kaufmann M

Sauerbrei W

Abstract

Purpose Current adjuvant therapies have improved survival for premenopausal patients with breast cancer but may have short-term toxic effects and long-term effects associated with premature menopause.Patients and methods The Zoladex Early Breast Cancer Research Association study assessed the efficac...

Discussions